June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
The potential of using different forms of human platelet lysates in the treatment of ocular surface problems
Author Affiliations & Notes
  • Lily Chen
    Ophthalmology, National Taiwan University Hospital, North Reading, Massachusetts, United States
  • Chien-Jung Huang
    Ophthalmology, National Taiwan University Hospital, North Reading, Massachusetts, United States
  • Yi-Chen Sun
    Ophthalmology, National Taiwan University Hospital, North Reading, Massachusetts, United States
  • Wen-Hui Tu
    Ophthalmology, National Taiwan University Hospital, North Reading, Massachusetts, United States
  • Fung-Rong Hu
    Ophthalmology, National Taiwan University Hospital, North Reading, Massachusetts, United States
  • Wei-Li Chen
    Ophthalmology, National Taiwan University Hospital, North Reading, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Lily Chen, None; Chien-Jung Huang, None; Yi-Chen Sun, None; Wen-Hui Tu, None; Fung-Rong Hu, None; Wei-Li Chen, None
  • Footnotes
    Support  104-CGN-15
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2634. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Lily Chen, Chien-Jung Huang, Yi-Chen Sun, Wen-Hui Tu, Fung-Rong Hu, Wei-Li Chen; The potential of using different forms of human platelet lysates in the treatment of ocular surface problems. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2634.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Autologous serum is commonly used to treat various ocular surface problems, but has major disadvantages during preparation. We hypothesize that human platelet lysate (HPL) can replace human peripheral serum (HPS) as treatment due to similar epitheliotropic abilities. We also cryoprecipitated HPL to evaluate the potential for future clinical use.

Methods : Liquid and cryoprecipitated forms of two commercialized HPLs, UltraGRO TM (Helios, Atlanta, GA) and PLTMax (Mill Creek, Rochester, MI), were compared with HPS and fetal bovine serum (FBS). Human corneal epithelial cells were incubated with various concentrations (0%, 3%, 5%, 10%) and preparations (liquid and cryoprecipitated forms) of these blood derivatives. Scratch-induced directional wounding assay was performed to evaluate cell migration while MTS assay was used to evaluate cell proliferation. Cell differentiation was examined by scanning electron microscopy, inverted microscopy and trans-epithelial electrical resistance. Sprague-Dawley rats were used to evaluate in vivo corneal epithelial wound healing after debridement and the topical application of blood derivatives at 2-hour intervals for 48 hours (N=3 per group; Total N=18). Concentrations of epidermal growth factor (EGF), transforming growth factor-β1 (TGF-β1), fibronectin, platelet-derived growth factor-AB (PDGF-AB), PDGF-BB and hyaluronic acid in blood derivatives were evaluated by enzyme-linked immunosorbent assay (ELISA).

Results : In vitro experiments on cell proliferation, migration and differentiation demonstrated that epitheliotropic abilities were not significantly different in the two commercialized HPLs compared to FBS and HPS (p>0.05). Among the different concentrations of blood derivatives, 3% samples yielded the best outcome (p<0.05). HPL produced better but not statistically different in vivo wound healing ability compared to FBS and HPS (p>0.05). Liquid and cryoprecipitated forms of HPL have similar concentrations of EGF, TGF-β1, fibronectin, PDGF-AB, PDGF-BB and hyaluronic acid, and demonstrated no significant difference in their epitheliotropic abilities (p>0.05).

Conclusions : Liquid and cryoprecipitated forms of commercialized HPL showed comparable corneal epitheliotropic abilities and wound healing rates compared to HPS and FBS. Results suggest that HPL can replace HPS in corneal epithelial treatments, pending further exploration in human clinical trials.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×